These data led to the US Food and Drug Administration approval of the THRβ agonist resmetirom as the first approved agent for treating adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis20,21. Here, THRB is linked to metabolic dysfunction-associated steatohepatitis.